SCHEMBL3429663

SCHEMBL3429663

Cc1c(-c2cccs2)nc2ccc(-c3cccc(CO)c3)cn12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 13/20 0.53
FYN P06241 1/20 0.47
CYP2C9 P11712 1/20 0.43
NR4A2 P43354 1/20 0.43
KCNH2 Q12809 1/20 0.43
GAA P10253 2/20 0.42
TP53 P04637 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PRKCI P41743 1/20 0.39
GABRD O14764 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRA4 P48169 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6521449 0.99 NR1H4 (0.52) NR1H4FYNCYP2C9NR4A2KCNH2
SCHEMBL6523662 0.84 CYP2C9 (0.48) NR1H4FYNCYP2C9NR4A2KCNH2
SCHEMBL3427891 0.83 NR1H4 (0.47) NR1H4GAATP53KDM4ENPC1
SCHEMBL220518 0.83 NR1H4 (0.45) NR1H4GAATP53KDM4ENPC1
SCHEMBL3409535 0.82 CYP11B1 (0.46) NR1H4NR4A2KCNH2GAATP53
SCHEMBL6525530 0.81 CYP2C9 (0.60) NR1H4CYP2C9NR4A2KCNH2ALDH1A1
SCHEMBL218008 0.79 NR1H4 (0.43) NR1H4FYNGAATP53ALDH1A1
SCHEMBL6520038 0.79 NR1H4 (0.47) NR1H4FYNCYP2C9NR4A2KCNH2
SCHEMBL6523594 0.78 CYP2C9 (0.48) NR1H4CYP2C9NR4A2KCNH2PRKCI
SCHEMBL3430234 0.78 NR1H4 (0.41) NR1H4GAATP53GABRDGABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP claimed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US claimed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP claimed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO claimed
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR1H4 400/4885FYN 267/4885CYP2C9 451/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR1H4 400/4885FYN 267/4885CYP2C9 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.